Loading...
BioMarin Pharmaceutical Community
NasdaqGS:BMRN Community- 2 Narratives written by author
- 0 Comments on narratives written by author
- 53 Fair Values set on narratives written by author
Community Investing Ideas
Pipeline Progress And Regulatory Support Will Unlock Rare Disease Opportunities
Key Takeaways Expanding global demand, new therapies, and strategic acquisitions strengthen BioMarin's revenue growth, market reach, and future pipeline potential. Operational efficiency, disciplined cost management, and regulatory advantages support sustained profitability and long-term margin stability.Read more
0users have liked this narrative
0users have commented on this narrative
32users have followed this narrative
AN
US$94.8
45.3% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
7.62% p.a.
Profit Margin
29.7%
Future PE
20.02x
Share price in 2028
US$115.63
Aging Global Demographics And Pipelines Will Expand Rare Therapies
Key Takeaways VOXZOGO's unique position, diagnosis initiatives, and international expansion are set to drive prolonged outsized sales and margin growth well beyond current expectations. Pipeline innovation, cost leverage, and savvy acquisitions position BioMarin for sustained margin expansion, new revenue streams, and enhanced long-term earnings growth.Read more
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$122
57.5% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
11.44% p.a.
Profit Margin
33.17%
Future PE
20.7x
Share price in 2028
US$148.24